A detailed history of Credit Suisse Ag transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 25,207 shares of MIRM stock, worth $867,877. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,207
Previous 24,078 4.69%
Holding current value
$867,877
Previous $710,000 10.85%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$24.92 - $30.02 $28,134 - $33,892
1,129 Added 4.69%
25,207 $633,000
Q4 2023

Feb 08, 2024

BUY
$27.14 - $34.93 $43,451 - $55,922
1,601 Added 7.12%
24,078 $710,000
Q3 2023

Nov 13, 2023

SELL
$24.63 - $32.85 $161,030 - $214,773
-6,538 Reduced 22.53%
22,477 $710,000
Q2 2023

Aug 11, 2023

BUY
$23.51 - $30.09 $293,616 - $375,794
12,489 Added 75.57%
29,015 $750,000
Q1 2023

May 10, 2023

BUY
$19.19 - $24.1 $86,259 - $108,329
4,495 Added 37.36%
16,526 $396,000
Q4 2022

Feb 13, 2023

SELL
$17.59 - $23.83 $2,532 - $3,431
-144 Reduced 1.18%
12,031 $234,000
Q3 2022

Nov 10, 2022

BUY
$19.98 - $29.44 $33,806 - $49,812
1,692 Added 16.14%
12,175 $255,000
Q2 2022

Aug 12, 2022

BUY
$18.42 - $27.5 $193,096 - $288,282
10,483 New
10,483 $204,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.27B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.